Metagenomi Therapeutics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.63
- 52-Week Range
- $0.60 – $1.87
- Market Cap
- $23.89M
- P/E (TTM)
- —
- EPS (TTM)
- -2.50
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 0.26
- PEG Ratio
- —
- Return on Equity
- -69.35%
- Return on Assets
- -30.83%
- Gross Margin
- 0.00%
- Operating Margin
- -1410.57%
- Profit Margin
- 0.00%
- Current Ratio
- 3.43
- Debt/Equity
- 0.39
- Total Debt
- $36.21M
- Free Cash Flow
- $-49.82M
- Revenue Growth
- -74.80%
- Earnings Growth
- —
- Enterprise Value
- $-41.58M
Market Snapshot
About
Metagenomi Therapeutics is a genetic medicines company developing gene editing and gene writing therapies. The company uses its proprietary metagenomics platform to discover novel genome editing systems for treating genetic diseases.